Poniard Pharmaceuticals, Inc. PARD

PARD Company Overview

Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) was a U.S.-based biopharmaceutical company focused on the development and commercialization of oncology therapeutics. The company primarily operated in the biotechnology and pharmaceutical industries, with its core efforts centered on anti-cancer drug candidates designed to improve efficacy and reduce toxicity relative to existing platinum-based chemotherapies. Its principal product candidate was picoplatin, a platinum-based chemotherapeutic agent investigated for the treatment of small cell lung cancer and other solid tumors.

The company evolved from NeoRx Corporation, a cancer-focused biotechnology business founded in the 1980s, before rebranding as Poniard Pharmaceuticals, Inc. in 2007 to reflect its strategic emphasis on oncology therapeutics. Poniard’s business model depended heavily on clinical development milestones, licensing arrangements, research collaborations, and access to capital markets rather than commercial product sales. Public filings and financial disclosures indicated that the company faced significant financial and regulatory challenges tied to the clinical progression of picoplatin, and operations were substantially reduced following unsuccessful late-stage development outcomes.